Related Experiment Video
Updated: May 9, 2026
05:50
Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
Published on: September 26, 2025
Models for open innovation in the pharmaceutical industry.
Alexander Schuhmacher1, Paul-Georg Germann, Henning Trill
1Reutlingen University, School of Applied Chemistry, Alteburgstrasse 150, 72762 Reutlingen, Germany.
Drug Discovery Today
|July 30, 2013
Summary
Pharmaceutical companies are adopting external innovation to combat declining research and development (R&D) productivity. This study identifies four new open innovator archetypes: knowledge creators, integrators, translators, and leveragers, defining current open R&D models.
Area of Science:
- Pharmaceutical industry innovation
- Biotechnology research and development
- Open innovation models
Background:
- The pharmaceutical industry's growth is intrinsically linked to innovation.
- Declining research and development (R&D) productivity poses a significant challenge.
- External innovation sourcing has become a strategic imperative for pharmaceutical firms.
Purpose of the Study:
- To identify and characterize emerging open innovator archetypes.
- To describe current open R&D models within the pharmaceutical sector.
Main Methods:
- Analysis of open innovation strategies in the pharmaceutical industry.
- Characterization of distinct roles within external R&D collaborations.
Main Results:
- Identification of four novel open innovator types: knowledge creator, knowledge integrator, knowledge translator, and knowledge leverager.
- These archetypes represent distinct approaches to leveraging external R&D.
Conclusions:
- The characterized open innovator types provide a framework for understanding contemporary pharmaceutical R&D strategies.
- Recognizing these roles can optimize external innovation sourcing and management.
Related Concept Videos
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
01:27Pharmacodynamic Models: Overview
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
01:06Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
01:20Pharmacokinetic Models: Overview
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...